Companion Animal Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Application, Technology, Animal, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Companion Animal Diagnostics Market size was worth USD 7.8 billion in 2026 and is expected to grow at a 8.84% CAGR between 2027 and 2036, surpassing USD 18.2 billion by 2036. The industry revenue for 2027 is calculated at USD 8.38 billion.

• Base Year Value (2026): USD 7.8 billion
• CAGR (2027-2036): 8.84%
• Forecast Year Value (2036): USD 18.2 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Companion Animal Diagnostics Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads with 40.18% share supported by mature veterinary infrastructure, high pet healthcare spending, and routine diagnostic integration across clinics and reference laboratories.
  • Asia Pacific growth is driven by rising pet ownership, expanding veterinary clinics, and increasing demand for early disease detection and preventive testing, supporting 10.85% CAGR.

• Segment Momentum:

  • Clinical Biochemistry captured 24.79% of the market in 2026 because it is routinely used for health assessments, organ function evaluation, and management of common chronic conditions in veterinary practice.
  • Molecular Diagnostics is the fastest-growing technology segment as veterinary providers increasingly seek higher-specificity testing and more precise identification of infectious and complex conditions.

• Market Expansion Drivers:

  • Rising pet ownership and increased spending on advanced veterinary diagnostic services.
  • Technological advancements in point-of-care molecular diagnostics and AI imaging systems.
  • Expansion of pet insurance and preventive wellness programs increasing diagnostic utilization frequency.

• Leading Market Participants:

  Leading companies in the companion animal diagnostics market include IDEXX Laboratories Inc. (United States), Zoetis Inc. (United States), Thermo Fisher Scientific Inc. (United States), Antech Diagnostics Inc. (United States), FUJIFILM Corporation (Japan), Virbac S.A. (France), bioMérieux SA (France), Neogen Corporation (United States), Embark Veterinary Inc. (United States), Esaote S.p.A. (Italy).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 7.8 billion
  • 2027 Estimated Market Size: USD 8.38 billion.
  • Projected Market Size: USD 18.2 billion by 2036
  • Growth Forecasts: 8.84% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Clinical Pathology (Application) | Clinical Biochemistry (Technology) | Dogs (Animal) | Diagnostic Laboratories (End Use)
  • Emerging Opportunity Segment: Clinical Pathology (Application) | Molecular Diagnostics (Technology) | Cats (Animal) | Point-Of-Care/In-House Testing (End Use)

Market Growth Drivers and Industry Trends

Rising pet ownership and increased spending on advanced veterinary diagnostic services

Higher pet ownership and greater willingness to spend on veterinary care are expanding demand for advanced diagnostic services for companion animals. The companion animal diagnostics market is benefiting as pet owners place greater emphasis on identifying health conditions early and accessing comprehensive veterinary care. Increased expenditure on animal healthcare supports the use of diagnostic testing for disease detection, clinical assessment, and ongoing health management, creating broader demand for diagnostic capabilities across veterinary practices.

Technological advancements in point-of-care molecular diagnostics and AI imaging systems

Technological progress in point-of-care molecular diagnostics and AI-enabled imaging is improving the speed, accessibility, and analytical capabilities of veterinary testing. Such innovations are strengthening the companion animal diagnostics market by enabling veterinary professionals to obtain more actionable information closer to the point of care and evaluate diagnostic images with greater technological assistance. Faster testing and advanced image interpretation can support more efficient clinical decision-making while expanding the range of diagnostic procedures available within veterinary settings.

Expansion of pet insurance and preventive wellness programs increasing diagnostic utilization frequency

The expansion of pet insurance and preventive wellness programs is encouraging more consistent use of veterinary diagnostic services by reducing barriers to routine and medically necessary testing. Within the companion animal diagnostics market, broader coverage and structured wellness initiatives can promote regular health assessments rather than relying solely on diagnostics when animals become visibly ill. More frequent veterinary visits create additional opportunities for screening, monitoring, and early identification of potential health issues, increasing the utilization of diagnostic procedures.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising pet ownership and increased spending on advanced veterinary diagnostic services	2.10%	Moderate	North America, Europe, Asia Pacific	High	Near Term
Technological advancements in point-of-care molecular diagnostics and AI imaging systems	1.80%	Moderate	North America, Europe, Asia Pacific	High	Near Term
Expansion of pet insurance and preventive wellness programs increasing diagnostic utilization frequency	1.40%	Moderate	North America, Europe	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America accounted for a 40.18% share of the companion animal diagnostics market in 2026, supported by high pet ownership, increasing expenditure on veterinary care, and widespread adoption of advanced diagnostic procedures. Veterinary practices are increasingly incorporating diagnostic testing into routine examinations and disease management, encouraging demand for faster and more accurate clinical decision-making. Greater emphasis on preventive animal healthcare and the humanization of pets is further supporting regular screening and diagnostic utilization.

In Asia Pacific, the companion animal diagnostics market is experiencing the fastest growth as pet ownership expands and veterinary healthcare becomes more sophisticated. Rising disposable incomes and changing attitudes toward companion animals are increasing willingness to spend on preventive and specialized care. Improvements in veterinary infrastructure, wider availability of diagnostic technologies, and growing awareness of early disease detection are helping broaden the use of diagnostic testing across both established and emerging markets.

Key Country Insights

United States

Preventive Veterinary Testing

The U.S. companion animal diagnostics market is shaped by growing emphasis on preventive veterinary care and advanced diagnostic services. Veterinary providers across the U.S. increasingly adopt rapid testing technologies and laboratory diagnostics to improve clinical decision-making and pet health management.

Japan

Advanced Companion Care

Japan continues expanding companion animal diagnostics through increased demand for sophisticated veterinary services and routine health screening. Diagnostic providers in Japan focus on accurate testing platforms that support chronic disease management and personalized veterinary care.

South Korea

Veterinary Technology Uptake

South Korea advances the companion animal diagnostics market by integrating modern diagnostic technologies into veterinary clinics. Demand in South Korea supports rapid point-of-care testing and digital diagnostic tools that improve workflow efficiency and enhance pet healthcare services.

Germany

Laboratory Diagnostics Expansion

Germany strengthens the companion animal diagnostics market through increasing use of laboratory testing and precision veterinary diagnostics. Veterinary practices in Germany invest in reliable diagnostic workflows that support earlier disease identification and more targeted treatment planning.

France

Preventive Pet Health Focus

France supports the companion animal diagnostics market through increasing emphasis on preventive care and routine veterinary screening. Diagnostic providers in France develop accessible testing solutions that help veterinarians detect health conditions earlier and improve treatment outcomes.

Italy

Clinic-Based Diagnostic Services

Italy expands the companion animal diagnostics market through broader adoption of in-clinic diagnostic systems and routine wellness testing. Veterinary professionals in Italy prioritize efficient diagnostic capabilities that support timely treatment decisions while enhancing the overall standard of companion animal care.

Segment Leadership and Growth Trends

 

Application Segment Analysis: Clinical Pathology (Largest & Fastest-Growing Segment)

Clinical pathology represented both the largest and fastest-growing application segment in the companion animal diagnostics market in 2026, accounting for 24.79% share. Its strong position reflects the central role of laboratory-based testing in identifying and monitoring common diseases and health conditions in companion animals. Increasing pet healthcare awareness, greater emphasis on preventive veterinary care, and rising demand for routine diagnostic screening are strengthening utilization of clinical pathology services. Veterinary professionals increasingly rely on laboratory findings to support timely diagnosis, treatment selection, and ongoing disease management, creating sustained demand for pathology-based diagnostic capabilities.

Technology Segment Analysis: Clinical Biochemistry (Largest Segment) vs Molecular Diagnostics (Fastest-Growing Segment)

Clinical biochemistry held the largest share of the technology segment in the companion animal diagnostics market in 2026, accounting for 24.79% share, driven by its broad applicability in assessing metabolic, organ, and general health conditions in companion animals. The routine nature of biochemical testing and its integration into veterinary health assessments support consistent utilization across clinical settings. Molecular diagnostics are expanding more rapidly as veterinarians increasingly seek sensitive and specific methods for identifying infectious diseases and other conditions at the molecular level. Advances in diagnostic precision and the growing importance of early disease detection are encouraging wider adoption of molecular techniques in companion animal healthcare.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Application	Clinical Pathology, Bacteriology, Virology, Parasitology, Others	Clinical Pathology	Clinical Pathology
Technology	Clinical Biochemistry, Immunodiagnostics, Hematology, Molecular Diagnostics, Urinalysis, Others	Clinical Biochemistry	Molecular Diagnostics
Animal	Dogs, Cats, Horses, Others	Dogs	Cats
End Use	Diagnostic Laboratories, Veterinary Hospitals and Clinics, Point-Of-Care/In-House Testing, Research Institutes and Universities	Diagnostic Laboratories	Point-Of-Care/In-House Testing

Competitive Landscape and Market Positioning

Major players in the companion animal diagnostics market:

1. IDEXX Laboratories Inc. (United States)

2. Zoetis Inc. (United States)

3. Thermo Fisher Scientific Inc. (United States)

4. Antech Diagnostics Inc. (United States)

5. FUJIFILM Corporation (Japan)

6. Virbac S.A. (France)

7. bioMérieux SA (France)

8. Neogen Corporation (United States)

9. Embark Veterinary Inc. (United States)

10. Esaote S.p.A. (Italy)

The companion animal diagnostics market is undergoing a profound transformation driven by the rapid integration of advanced screening technologies. Veterinary care is shifting toward automated, high-precision tools that allow for real-on-site testing and faster clinical decisions. This widespread upgrade in clinical capabilities is largely supported by specialized research alliances, which pull cutting-edge molecular techniques out of the lab and directly into regular veterinary clinics to meet the rising expectations of pet owners.

Industry Development/News

Company Name	Date	Key Development
Zoetis	Nov-25	Zoetis acquired the Veterinary Pathology Group (VPG), a prominent diagnostic laboratory network operating across the UK and Ireland. This acquisition serves as a strategic milestone, granting Zoetis its first owned reference laboratories in the region and enhancing its ability to provide integrated diagnostic services, combining point-of-care solutions with sophisticated reference lab capabilities.
Zomedica	Sep-25	Zomedica expanded its intellectual property portfolio through the issuance of four U.S. patents covering its TRUVIEW digital cytology and TRUFORMA diagnostic platforms. By strengthening its protections around automated slide processing and sensor technology, Zomedica bolsters its competitive positioning and long-term ability to capture market share within the rapidly scaling veterinary diagnostics sector.
Hill’s Pet Nutrition	May-25	Hill’s Pet Nutrition formed a strategic partnership with MiDOG Animal Diagnostics to integrate advanced microbiome sequencing into veterinary care and nutrition research. The collaboration aims to leverage high-precision microbial diagnostics to guide targeted clinical treatments and develop personalized nutritional solutions, representing a shift toward data-driven, precision health management for companion animals.
IDEXX	Jan-25	IDEXX introduced IDEXX Cancer Dx, a cost-effective, routine blood screening tool designed for the early detection of canine lymphoma. By simplifying access to oncological diagnostics, this launch targets a significant unmet need in general veterinary practice, enabling earlier intervention for at-risk patients and expanding the company's footprint in the growing veterinary oncology segment.
Antech Diagnostics	Jan-25	Antech Diagnostics launched the truRapid FOUR lateral flow test, a comprehensive screening solution for common canine vector-borne diseases. This proprietary diagnostic platform enables rapid, multi-pathogen detection—including Anaplasma, Ehrlichia, Lyme, and heartworm—from a single sample, enhancing operational efficiency and diagnostic throughput at the point of care for veterinary practitioners.
Zoetis	Sep-24	Zoetis launched the Vetscan OptiCell, a cartridge-based hematology analyzer utilizing AI-powered technology to deliver point-of-care Complete Blood Count (CBC) analysis. The system provides lab-quality diagnostic results with increased speed and reduced spatial requirements, supporting a trend toward greater clinical decentralization and enhancing the efficiency of diagnostic workflows in busy veterinary settings.
Oxford BioDynamics	Jun-24	Oxford BioDynamics developed the EpiSwitch SCB test, a non-invasive blood-based diagnostic capable of distinguishing between six common canine cancers with high accuracy. This technology offers a novel alternative to more invasive biopsy procedures, providing veterinarians with a clinically significant tool to improve the early detection and management of complex malignancies in canine patients.